Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Unknown 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Genitourinary 3

Conditions

Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × vorolanib × Thoracic × Clear all
NCT04373369 2025-11-03

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Washington University School of Medicine

Phase 2 Terminated
11 enrolled 10 charts
Thoracic

Small Cell Lung Carcinoma

NCT03848611 2020-07-09

CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

AnewPharma

Phase 2 Unknown
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03904719 2020-07-09

CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)

AnewPharma

Phase 2 Unknown
30 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡